Skip to main content

The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma (ICPT) - Get Intercept Pharmaceuticals, Inc. Report offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech trading 2014 compared to 2013. 

Here are the charts:

^NBI data by YCharts

Image placeholder title

And here's what the NBI looked like for the first 9 days of 2013:

^NBI data by YCharts

TheStreet Recommends

Image placeholder title

One big difference between 2013 and 2014 to note: The J.P. Morgan Healthcare Conference ran early last year -- Jan. 7-10, 2013, so investors were already reacting to what was an incredibly upbeat outlook offered by biotech companies. 

This year's J.P. Morgan confab starts on Monday and runs through Thursday, so we'll check back on these charts late next week to see if 2014 catches up to 2013's performance. 

Intercept is obviously the best-performing drug stock in this very young 2014, but other stocks strong out of the gate include Neurocrine Bioscience (NBIX) - Get Neurocrine Biosciences, Inc. Report, Epizyme (EPZM) - Get Epizyme, Inc. Report, Zalicus ZLCS, Oramed Pharma (ORMP) - Get Oramed Pharmaceuticals Inc. Report and Atherthys (ATHX) - Get Athersys, Inc. Report. In other words, the speculative fervor we saw last year has not abated. 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.